Results

Total Results: 29 records

Showing results for "hospital-associated venous thromboembolism".

1. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2002
   July 08, 2002 - incidence between the tamoxifen and placebo groups in this age group. 7 The relative risk increase in venous … thromboembolism from tamoxifen or raloxifene appears similar to the risk for venous thromboembolism

2. Chemoprevention of Breast Cancer - Recommendations and Rationale (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/MnkNvteY4Yg_8Jut4SayVN
   July 02, 2002 - incidence between the tamoxifen and placebo groups in this age group.7 The relative risk increase in venous … thromboembolism from tamoxifen or raloxifene appears similar to the risk for venous thromboembolism

3. Evidence Summary: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction
   September 03, 2019 - with tamoxifen 0.97 (0.86-1.12) 2 NA NA 1.05 (0.87-1.28) 2 NA NA Harms Venous … thromboembolism j 0.75 (0.60-0.93) d 4 (1-7) more with tamoxifen 1.93 (1.33-2.68) 4 0.91 ( … Project; PE, pulmonary embolism; RR, risk ratio; RUTH, Raloxifene Use for the Heart; SE, standard error; VTE … , venous thromboembolism.

4. Evidence Summary: Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/vitamin-d-calcium-or-combined-supplementation-for-the-primary-prevention-of-fractures-in-adults-preventive-medication
   April 17, 2018 - thromboembolism) were included. … thromboembolism, and heart failure outcomes. … thromboembolism, and hospitalization for heart failure were also reported (stroke: ARD, −0.09% [95% … CI, −0.38% to 0.20%] and HR, 0.95 [95% CI, 0.82 to 1.10]; venous thromboembolism: ARD, −0.16% [95% CI … The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism: from the

5. Archived: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction-2013
   September 15, 2013 - general, women taking medications for breast cancer risk reduction are less likely to experience a VTE … Women with a personal or family history of venous thromboembolism are at higher risk for these adverse

6. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/-TsBkyewVoFpC7htRmzWJa
   September 03, 2019 - Project; PE, pulmonary embolism; RR, risk ratio; RUTH, Raloxifene Use for the Heart; SE, standard error; VTE … , venous thromboembolism. a Numbers of events reduced for benefits or increased for harms vs comparator

7. VitaminD, Calcium, or Combined Supplementation for the Primary Prevention of Fractures in Community-Dwelling Adults: Evidence Report and Systematic Review for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/Yc24U4wMLXGoqE5NjwRVA6
   April 17, 2018 - thromboembolism) were included. … thromboembolism, and heart failure outcomes. … thromboembolism, and hospitalization for heart failure were also reported (stroke: ARD, −0.09% [95% … thromboembolism: ARD, −0.16% (95% CI, −0.44% to 0.12%); HR, 0.92 (95% CI, 0.79 to 1.07) Heart failure … The effect of calcium plus vitamin D supplementation on the risk of venous thromboembolism: from the

8. Zvvry6Wa4Sgj-Ejb3Brcvy (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/zVVRY6wa4Sgj-EJb3BRcVy
   November 01, 2013 - Effects In general, women receiving medications for breast cancer risk reduction are less likely to have VTE … Women with a personal or family history of venous thromboembolism are at higher risk for these ad- verse

9. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction-2002
   May 06, 2002 - The relative risk increase in venous thromboembolism from tamoxifen or raloxifene does not appear to … Risk of venous thromboembolism in users of hormone replacement therapy.

10. Chemo and Couns/2nd instal (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-hnLT26c2NHs6thK9yznPF
    July 01, 2002 - The relative risk increase in venous thromboembolism from tamoxifen or raloxifene does not appear to … Risk of venous thromboembolism in users of hormone replacement therapy.

11. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary27/breast-cancer-medications-for-risk-reduction-2013
    April 15, 2013 - Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention

12. Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review of the USPSTF (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/7ZSKduUYHWKe7q_tTY9xbF
    April 01, 2013 - Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention

13. Screening for Osteoporosis in Postmenopausal Women - Recommendations and Rationale (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/nnkwqkX-Nk6v3gsphVATUD
    September 01, 2002 - Screening for Osteoporosis in Postmenopausal Women - Recommendations and Rationale Summary of Recommendations • The U.S. Preventive Services Task Force (USPSTF) recommends that women aged 65 and older be screened routinely for osteoporosis. The USPSTF recommends that routine screening begin at age 60 for women at i…

14. Archived: Osteoporosis: Screening, 2002 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening-2002
    September 17, 2002 - Share to Facebook Share to X Share to WhatsApp Share to Email Print archived Final Recommendation Statement Osteoporosis: Screening, 2002 September 17, 2002 Recommendations made by the USPSTF are independent of the U.S. government. They sho…

15. Final Recommendation Statement: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/RecommendationStatementFinal/breast-cancer-medications-for-risk-reduction
    September 03, 2019 - ) events, or stroke. 3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

16. Archived: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/osteoporosis-screening-june-2018
    June 26, 2018 - Health Initiative trial, the previous review found an increased rate of gallbladder events, stroke, and venous … thromboembolism with estrogen therapy, and an increased risk of urinary incontinence during 1 year of … invasive breast cancer, coronary heart disease, probable dementia, gallbladder events, stroke, and venous … thromboembolism compared with women taking placebo, and an increased risk of urinary incontinence during

17. Recommendation: Breast Cancer: Medication Use to Reduce Risk | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/breast-cancer-medications-for-risk-reduction
    September 03, 2019 - ) events, or stroke. 3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

18. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/3Kwu7j_WfCFQSnSzqrDWwt
    June 20, 2019 - CHD) events, or stroke.3 When compared with placebo, raloxifene was associated with 7 more cases of VTE … on the STAR trial, more harms were reported with tamoxifen compared with raloxifene: 4 more cases of VTE

19. Screening for Osteoporosis to Prevent Fractures: USPSTF Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/ffNDS7ekxovstoCxxtLJVt
    February 13, 2018 - Initiative trial, the previous review found an increased rate of gall- bladder events, stroke, and venous … thromboembolism with estro- gen therapy, and an increased risk of urinary incontinence during 1 year

20. Archived: Carotid Artery Stenosis: Screening, 1996 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/recommendation/carotid-artery-stenosis-screening-1996
    January 01, 1996 - Share to Facebook Share to X Share to WhatsApp Share to Email Print archived Final Recommendation Statement Carotid Artery Stenosis: Screening, 1996 January 01, 1996 Recommendations made by the USPSTF are independent of the U.S. governmen…